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Mycobacterium ulcerans infection is responsible for severe skin
lesions in sub-Saharan Africa. We enrolled 30 Beninese pa-
tients with Buruli ulcers in a pilot study to evaluate efficacy of
an oral chemotherapy using rifampicin plus clarithromycin
during an 8-week period. The treatment was well tolerated, and
all patients were healed by 12months after initiation of therapy
without relapse.
Mycobacterium ulcerans is the causative agent of Buruli ulcer, an
emerging tropical disease marked by devastating skin lesions [1].
Buruli ulcer affects mainly children in rural areas, where access to
health care is often delayed and where lengthy hospital stays are
problematic. Until recently, surgery was the only treatment for
Buruli ulcer. Significant progress has been made in the past 5
years with the demonstration of the efficacy of rifampicin plus
streptomycin (R 1 S) chemotherapy [2]. Its routine imple-
mentation has dramatically improved healing while reducing the
frequency of relapses [3]. However, streptomycin is an injectable
drug, and the lack of an efficacious oral treatment remains one of
the main obstacles to decentralizing care at local level.
A recently published randomized controlled trial from Ghana
showed no significant difference in the proportion of patients
who achieved cure after receiving the World Health Organization
(WHO)–recommended 8-week course of R 1 S chemotherapy,
compared with the proportion who achieved cure after receiving
a treatment consisting of 4 weeks of R 1 S followed by 4 weeks of
rifampicin 1 clarithromycin (R 1 C) [4].
This study represents a significant step to improve Buruli ulcer
treatment. Indeed, clarithromycin is orally administered and is
better tolerated than streptomycin, which requires daily injections
and is associated with adverse events, such as vestibular toxicity
(which occurs in 0.5%–5% of patients) and nephrotoxicity (which
occurs in 5%–10%) [5]. A clarithromycin-based oral treatment
would be more easily administered, better accepted by patients,
and contribute to limiting the number of injections in the de-
veloping world [6]. Implementation of an oral R 1 C chemo-
therapy is supported by recent evidence of its bactericidal activity
in vivo [7, 8] and by several clinical successes [9, 10].
Here, we report a pilot study involving 30 patients with Buruli
ulcer disease treated using an oral combination of rifampicin
and clarithromycin over an 8-week period. All patients were
successfully healed, and no adverse event was observed.
MATERIALS AND METHODS
This study was realized at the Centre de Diagnostic et de
Traitement de l’Ulce`re de Buruli (CDTUB) in Pobe`, Benin. El-
igible patients had laboratory-confirmed cases of Buruli ulcer,
were at least 5 years of age, presented with lesions <10 cm in
diameter that had appeared within the past 6 months, agreed to
be hospitalized during treatment, and were likely to be followed
up for 18 months (ie, had stable habitation). Written informed
consent was obtained from the patient and from the patient’s
parent or guardian if the patient was under 18 years of age.
Noninclusion criteria were lesions .10 cm in diameter,
multiple lesions, lesions located over a joint, history of treatment
with antimycobacterial drugs, receipt of macrolide or quinolone
antibiotics during the previous month, allergy to rifampicin or
clarithromycin, pregnancy, or human immunodeficiency virus
infection. All nonincluded patients were treated according to
WHO guidelines.
The primary end point was defined as healing of the wound at
12 months, without recurrence 18 months after initiation of
chemotherapy. Patients were treated using an oral combination
of rifampicin (10 mg/kg) and clarithromycin (12 mg/kg) ad-
ministered simultaneously, once daily, over 8 weeks.
During treatment, patients were hospitalized and attended to
daily by nursing staff, who dispensed chemotherapy with a fatty
snack and monitored patients for adverse effects during a 1-h
period after treatment intake. Clarithromycin was administered
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as 250-mg tablets completed with syrup to achieve exact dose.
Nursing staff cleansed the wound using physiological solution
and renewed the wound dressing using simple sterile dressings.
Every week, patients were examined by a doctor, who also col-
lected samples at week 4, 6, and 8 if the lesion had not healed,
using swabs or aspiration. These samples were sent for
M. ulcerans culture and polymerase chain reaction (PCR) anal-
ysis. After the wound closed, patients were discharged from the
hospital and were followed-up every 3 months up to 18 months
after starting treatment.
Limited surgery was defined as curettage of the lesion or
a minor excision to remove excess granulation tissue and to
debride ulcer margins. Extensive surgery was defined as major
excision followed by skin-grafting. Surgery was undertaken if:
(1) no improvement or an aggravation of the lesion character-
istics was observed at week 4 of chemotherapy or after, (2)
induration persisted 12 weeks after initiation of chemotherapy,
(3) the lesion started bleeding at any time, or (4) the lesion
showed signs of improper scaring and risks of functional in-
capacities at any time. Excised tissue was sent for histological
analysis, as well as M. ulcerans culture and PCR.
All biological samples were collected and handled identically
according to WHO guidelines. Blinded analysis of samples was
performed at the laboratory in Angers, France, along with
routine microbiological analyses for the CDTUB.
Ethical approval for this study was given by the Ministry of
Health in Benin. Technical approval was given by the WHO
Buruli ulcer working group on chemotherapy.
RESULTS
Patients were enrolled consecutively from December 2007
through February 2009. Included patients represented one-third
of eligible patients who received a diagnosis during this period.
The main reason for nonparticipation was refusal of hospitali-
zation. Twelve of the patients were male, and 18 were female; 11
were .15 years of age. Nine patients presented with non-
ulcerative lesions, and 21 presented with ulcerative lesions.
Buruli ulcer diagnosis was confirmed by PCR for all patients,
and 13 patients (43%) had a positive culture result at enrolment.
Treatment was well tolerated, and no adverse events were
reported. All patients had reached 18 months of follow-up by
September 2010.
All 30 patients were successfully treated, with complete re-
epithelialization of wounds 12months after treatment initiation,
and no patient experienced relapse during follow-up. The me-
dian duration of healing was 104 days (range, 30–212 days; see
Table 1 and supplementary Table 1 for individual data).
Microbiological follow-up was performed at week 4, 6, and 8
on lesions that remained open. Culture results became negative
for all sampled patients except 1 after 4 weeks; no culture was
positive after 6 weeks. PCR follow-up of lesions that remained
open showed that negative PCR results were rarely obtained
before scarring (supplementary Table 2).
Among those 30 patients, 15 (50%) healed after chemother-
apy without any additional intervention (Table 1), and 11 (37%)
of the patients underwent limited surgical procedures, such as
curettage (n 5 9) or excision (n 5 2). These procedures were
mainly undertaken without suspicion of failure to promote
a faster and more regular scaring of lesions presenting excessive
granulation or risks of functional incapacities.
Four patients, 6–8 years of age, underwent extensive surgical
excision followed by skin grafting. Three patients presented with
category 2 lesions that were large for their body size and either
worsened or showed no improvement (supplementary Table 1).
One patient who had previously healed without surgery expe-
rienced trauma at the site of the scar and required secondary
extensive surgery.
As observed in our routine experience of R 1 S chemother-
apy [3], R 1 C chemotherapy was also sufficient to cure most (8
of 10) patients with category 1 ulcerative lesions and to cure 5 of
11 patients who presented with larger ulcerative lesions. A ma-
jority of nonulcerative lesions (7 of 9) required additional sur-
gical procedures.
Tissue specimens were collected from the 15 patients who
underwent surgery. Of 14 samples analyzed in culture, none was
Table 1. Outcome and Additional Care received in 30 Patients with Buruli Ulcer Disease Treated with Oral Rifampicin plus















Ulcerative 1 8 2 0 10 38
2 5 4 2* 11 115
Non ulcerative 1 2 1 0 3 109
2 0 4 2 6 111
Total 15 (50) 11 (37) 4* (13) 30 (100) 104
a Category 1, lesion diameter ,5 cm; category 2, lesion diameter 5–10 cm.
* Including one patient healed with chemotherapy alone who required secondary skin-grafting after experiencing trauma on the scar site.
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positive for M. ulcerans. However, 13 patients had a positive
PCR result, suggesting persistence of mycobacterial material, as
described by others [2].
DISCUSSION
In this pilot study, 30 patients with confirmed Buruli ulcer
disease were successfully healed using R1C chemotherapy.
Microbiological results indicate that persistence of viable my-
cobacteria was unlikely, even when extensive surgery was re-
quired. Histological analysis supports this point, showing that
10 of 11 samples analyzed presented evidence of massive in-
flammatory infiltration. Local inflammatory reactions and the
development of ectopic lymphoid tissue have been observed in
Buruli ulcer lesions during healing while receiving chemother-
apy [11, 12]. This most likely results from mycobacterial anti-
gens and immunostimulators released during chemotherapy. In
our experience, as confirmed by others [13], this reaction is
associated with good response to treatment and occurs irre-
spective of the chemotherapy used (A.C., unpublished data).
We advocate that additional chemotherapy efficacy studies
should rely on an improved definition of treatment failure that
includes microbiological evidence of viable, treatment-resistant
mycobacteria and histological assessment of inflammatory re-
action. Clinical criteria do not provide a clear rule to discrimi-
nate between patients who experience chemotherapy failure and
patients who successfully clear the infection but require surgery
to expedite the healing process.
In the Ghanaian trial, treatment failure was defined according
to clinical criteria, such as lesion size progression or the need for
extensive surgery, for all but one of the patients who experienced
treatment failure [4]. The subjective component of such clinical
criteria makes it difficult to compare results across different
studies. In our study, 3 patients required extensive surgery, but
none presented persistence of viable mycobacteria.
Positive cultures were obtained in Ghana after treatment
completion in 5 patients who belonged to the 4 weeks of R 1 S
followed by 4 weeks of R 1 C arm [4]. This result is difficult to
interpret without information on drug resistance or possible re-
infections. In our study, viable mycobacteria were not observed
after 6 weeks of treatment. We hypothesize that our higher
dosage of clarithromycin was more efficient at clearing the in-
fection, without causing more adverse effects.
In conclusion, this study provides compelling evidence to
support a future randomized controlled trial that compares the
standard regimen (8 weeks of R 1 S) with the complete oral
regimen (8 weeks of R 1 C). Proving the efficacy of the R 1 C
combination could lead to a simpler, less invasive, and less
painful treatment that is easier to implement at the local level.
Surgery is likely to remain necessary for severe lesions, but
a large proportion of patients can be cured through oral
chemotherapy alone, which is a great boon to the rural com-
munities most affected by Buruli ulcer.
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